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The application of nucleoside analogue-based chemotherapy and immunotherapy with rituximab or alemtuzumab has increased
both response rate and survival in patients with Chronic Lymphocytic Leukemia (CLL). However, because none of these therapies
is curative, sequential therapeutic regimens are required. The majority of patients with relapsed or refractory CLL carry poor
prognostic factors and show shorter overall survival and resistance to standard treatment. Numerous drugs have recently been
approved for CLL therapy and many novel agents are under clinical investigation. The role of the tumor microenvironment and
of immune dysfunction in CLL have allowed to enlarge the therapeutic armamentarium for CLL patients. This article will provide
a comprehensive summary regarding mechanism of action, eﬃcacy and safety of lenalidomide in CLL patients. Relevant clinical
trials using lenalidomide alone or in combinations are discussed. Lenalidomide shows good activity also in relapsed/refractory or
treatment-naive CLL patients. Definitive data from ongoing studies are needed to validate overall and progression-free survival.
The toxicity profile might limit lenalidomide use because it can result in serious side eﬀects, but largely controlled by gradual dose
escalation. Further understanding of the exact mechanism of action in CLL will allow more eﬃcacious use of lenalidomide alone
or in combination regimens.
1. Introduction
Chronic lymphocytic leukemia (CLL) shows a remarkable
heterogeneity in its clinical course, from long-term survival
to fast progression and early death. Previously treated pa-
tients are known to have poor overall prognosis. In such
cases, the disease almost invariably becomes resistant to var-
ious subsequent chemotherapies, leading to more toxicities
and deterioration of quality of life.
Fludarabine given with cyclophosphamide and ritux-
imab is considered the cornerstone of CLL treatment, but
this eﬀective chemoimmunotherapy cannot be given with the
same success to all patients. The majority of patients with
relapsed or refractory CLL carry poor prognostic features,
like, deletion (17p) or TP53 mutation, which are strong pre-
dictors of shorter overall survival and resistance to first-line
treatment, particularly fludarabine-based regimens [1, 2].
The management of chronic lymphocytic leukemia is
currently undergoing profound changes through the intro-
duction of new therapeutic and diagnostic tools.
A common feature of CLL patients is impairment of
the immune systemwith hypogammaglobulinemia, defective
function of B, T, NK cells and defective antigen presenta-
tion [3]. Immunomodulatory drugs, such as, lenalidomide,
represent a promising approach for relapsed/refractory or
treatment-naı¨ve patients, because they show antitumor acti-
vity and promote immunostimulation.
2. Mechanisms of Action of
Lenalidomide in CLL
The precise anti-CLL mechanism of action of lenalidomide
is not yet completely defined. Potential mechanisms of
action include antiangiogenic eﬀect, blockade of protumor
cytokines, inhibition of prosurvival interaction between
bone-marrow stromal cells and CLL cells, and enhancement
of T helper and cytotoxic T cells function [4].
Immunomodulatory eﬀects of lenalidomide include a
costimulatory eﬀect on T-cell responses by increasing IL-2
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and INF-gamma secretion and subsequently proliferation of
IL-2-activated T cells. Eﬀects of lenalidomide in the produc-
tion of cytokines is shown by increased circulating cytokines
levels, particularly, IL-6, IL-10, IL-2, and TNF-receptor-
1 levels; while it is a potent inhibitor of tumor necrosis
factor alpha (TNF-alfa), this inhibition may results from
increased degradation of TNF-alfa mRNA [5, 6]. Data from
LeBlanc suggest that lenalidomide activates T lymphocytes
directly by increased phosphorylation of CD28 and increased
transcriptional activity of AP-1 and indirectly by enhancing
immune synapses between antigen-presenting cells and
eﬀector T cells [7–9].
Lenalidomide exposure is able to lead to immune synap-
ses between CLL cells and T cells and promotes costimulatory
activation of B cells. During treatment with lenalidomide
in CLL patients an increase in circulating Ig levels has been
observed. This increased production of Igs may be explained
by enhanced B-cell costimulatory activity via activation of
lymphocytes through phosphoinositide-3-kinase dependent
upregulation of CD154 (CD40L) on CLL cells, as described
by Lapalombella et al. [10].
The immune activation of CLL cells with subsequent
upregulation of costimulatory molecules, such as, CD40,
CD80 and CD86, might be responsible for Tumor Flare
observed in CLL patients treated with lenalidomide [6].
Lenalidomide has also been shown to activate NK T cells; one
of its postulated mechanisms of action is increased antibody-
dependent cellular cytotoxicity (ADCC). IL-2-activated T
cells are able to activate NK cells enhancing tumor cell death
[5, 7, 11].
Many tumors, including CLL, are characterized by
increased number of T regulatory cells and expression of
CD152 (CTLA4) in T cells with a correlation with advanced
disease and adverse prognostic factors. Lenalidomide reduces
T regulatory cell proliferation and suppression function [12].
Lenalidomide also shows antiangiogenic properties in
vitro. However, Andritsos et al. [13] reported that VEGF se-
rum concentrations remained unchanged in patients treated
with lenalidomide. Furthermore, Ferrajoli et al. [6] did not
observe changes in neovascularization in the bone marrow
biopsies in patients treated with lenalidomide.
3. Clinical Results Utilizing
Lenalidomide in CLL
3.1. Clinical Studies with Lenalidomide as Single Agent in CLL.
The second-generation immunomodulatory agent lenalido-
mide has shown considerable activity in CLL, either alone or
in combinations and both as first-line and salvage treatment.
Activity in CLL was first demonstrated by Chanan-Khan
et al. [14] in a nonrandomized phase II study that included
patients with relapsed or refractory B CLL. In this trial
25mg of lenalidomide was administered every 21 days of a
28-day cycle in 45CLL patients. Patients were to continue
treatment until disease progression, unacceptable toxicity, or
complete remission. The major overall response rate (ORR)
in this study was 47%, with a complete response (CR) rate
of 9%. Tumor lysis syndrome (TLS) and tumor flare reaction
(TFR) occurred in 5% and 58% patients, respectively. TLS
is characterized by electrolyte imbalance, uremia, and renal
failure, while TFR is associated with painful swelling of
lymph nodes and/or splenomegaly with sometimes fever and
skin rash.
Because of toxicity, including tumor lysis syndrome in
two of the first 29 patients, the dosing schedule was modified
and the new treatment schema stipulated a dose escalation
beginning at 5mg/day and a target dose of 25mg/day. None
of the patients (with or without the prophylaxis) required
interruption, discontinuation, or dose reduction of therapy
because of flare reaction.
Together with TFR, fatigue (83%) was the most common
nonhematologic adverse event reported. Grades 3 or 4 neu-
tropenia, thrombocytopenia, and anemia occurred in 70%,
45%, 18% patients during therapy, respectively. There were
six episodes of febrile neutropenia. Although neutropenia
was observed in a subset of patients, neither opportunistic
nor bacterial infections were problematic in this heavily
pretreated group of patients. Pulmonary embolism occurred
in two patients.
In another clinical trial of lenalidomide in pretreated CLL
patients [6], 44 patients received lenalidomide continuously
at 10mg/day with a dose escalation up to 25mg/day. Treat-
ment was discontinued if disease progression or excessive
toxicity was observed. In this pretreated group of patients,
ORR was 32%, with 7% achieving a CR. The most common
toxicity was myelosuppression, and the median daily dose
of lenalidomide tolerated was 10mg. Severe neutropenia,
thrombocytopenia, and anemia were reported in 41%, 15%,
and 3% of patients. None of the 44 patients had grade
3 or 4 episodes of tumor lysis; however, the incidence of
TFR at any grade was higher in patients with lymph nodes
larger than 5 cm (53%); grade 3 tumor flare reaction was
reported in 2% of the courses and grade 1 or 2 tumor flare
was reported in 10% of the courses. The most common
infection was pneumonia, complicating 3% of the courses.
FUO was observed in 2% of the courses. The median daily
dose of lenalidomide tolerated by the patients in this study
was 10mg, and only 3 patients (7%) were able to tolerate the
dose of 25mg daily for at least 1 month. Myelosuppression
was the most frequent reason for treatment interruption and
dose reduction. Nonhematologic toxicity consisted of grade
1 to 2 fatigue, observed in 22% of the courses and grade
3 to 4 in only 1%. Only one case of deep vein thrombosis
was reported, suggesting that this complication may be more
common when lenalidomide is used in association with
steroids and in patients with plasma cell dyscrasias.
Treatment with lenalidomide was associated with an
ORR rate of 31% in patients with 11q or 17p deletion, of
24% in patients with unmutated VH, and of 25% in patients
with fludarabine-refractory disease.
Sher et al. [15] reviewed the cases of relapsed/refractory
CLL patients with high-risk cytogenetics who were included
in the trial of Chanan-Khan et al. [14]; clinical response was
reported in 38% of these patients, with 19% CR.
The question of whether continuous exposure is superior
to the 3 weeks on/1 week oﬀ schedule reported by Chanan-
Khan et al. [14] will require further investigation.
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While data from Ferrajoli et al. [6] and Chanan-Khan et
al. [14] proposed an escalation dose up to 25mg, a report
from Andritsos et al. [13] described serious adverse events
four patients with relapsed CLL treated with lenalidomide
(25mg/d for 21 days of a 28-day cycle). Tumor flare was
observed in three patients and was characterized by dramatic
and painful lymph node enlargement resulting in hospital-
ization of two patients, with one fatal outcome. Another
patient developed sepsis and renal failure.
Chen et al. [16] reported results of lenalidomide therapy
in 25 previously untreated patients. Lenalidomide dosing
involved an escalation starting from a dose of 10mg up to
25mg/day. Serious toxic complications (tumor lysis and fatal
sepsis) occurred in the first two patients, the protocol was
modified with a 2,5mg starting dose and an escalation up to
10mg as target dose. Twenty-two patients were treated with
this schema. The ORR was 56%, no CR. TFR was evident in
88% of patients, mostly low grade.
In a phase II study Aue et al. [17] reported a change in
administration schedule of lenalidomide, which was given
in pulse dosages for 3 weeks followed by 3 weeks oﬀ. This
study involved high-risk pretreated patients with a poor
prognosis: 52% was Rai stage III-IV, 43% had del(17p), and
64% expressed unmutated IgVH genes. Lenalidomide was
administered at 10 mg daily for 21 days of a 42-day cycle, for
a total of 4 cycles. Grade 3-4 neutropenia, thrombocytopenia,
and anemia occurred in 56%, 30%, and 15% of cycles,
respectively. No TLS cases were seen. However, the hypothe-
sis of achieving a safer and more tolerable toxicity profile was
not obtained, since TFR was observed in 78%, 48%, 38%,
and 30% in 1st, 2nd, 3rd, and 4th cycle, respectively. ORR
was only 16% but patients with del(17p) and bulky disease
appeared to have a remarkable PR rate of 80%
Badoux et al. [18] investigated lenalidomide for elderly
untreated CLL patients. Lenalidomide was administered to
sixty patients 65 years of age and older at 5mg daily with a
possible dose escalation of 5mg every 28 days up to 25mg
daily. At a median followup of 29 months, 53 patients (88%)
were alive and 32 patients (53%) remained on therapy. Esti-
mated 2-year progression-free survival was 60%. The overall
response rate to lenalidomide therapy was 65%, including
10% CR, 5% CR with residual cytopenia. Neutropenia was
the most common grade 3 or 4 treatment-related toxicity
observed in 34% of treatment cycles. Major infections or
neutropenic fever occurred in 13% of patients. There were
no grade 3 or 4 episodes of tumor flare or any tumor lysis
syndrome in this study. Also compared with baseline levels,
the authors noted an increase in serum immunoglobulin
levels across all classes.
According to these several studies, TFR is a common
toxicity described with lenalidomide. Because of its high
incidence, its considerable morbidity and its clinical pre-
sentation resembling disease progression, an early diagnosis,
and an accurate management are critical for eﬀective use of
lenalidomide in patients with CLL.
Often TFR included a sudden onset of painful and tender
enlargement of disease-involved lymph nodes, the spleen,
and/or liver, which was frequently accompanied by low-
grade fever, localized erythema, or generalized rash (often
diﬀuse, erythematous, nonpruritic, and maculopapular) and
occasionally associated with bone pain. Patients who develop
a TFR tend to have a higher stage of disease, but mostly there
is no significant diﬀerence noted with regard to the incidence
of TFR among patients with bulky versus nonbulky disease.
The severity of TFR can be graded according to the Na-
tional Cancer Institute Common Toxicity Criteria [i.e. grade
1, mild pain not interfering with function grade 2, moderate
pain (pain or analgesics interfering with function, but not
interfering with activities of daily living); grade 3, severe pain
(pain or analgesics interfering with function and activities of
daily living); grade 4, disabling pain].
The identification and careful characterization of a TFR
are important in the treatment of CLL patients with lenalido-
mide to avoid unnecessary morbidity or the premature
discontinuation of eﬀective therapy. It’s recommended close
monitoring of patients with CLL for signs of TFR, especially
during the first days of lenalidomide therapy and treatment
with an NSAID,such as, ibuprofen (at a dose of 400–600 mg
every 6 hours), with steroid use considered only in cases of
more intense TFRs.
A slow-dose escalation strategy may reduce the intensity
of TFR and should be considered, such as, reported by
Chanan-Khan et al. [19] Eventually, dose adjustment of lena-
lidomide can be use in case of severe TFR, the dose can be
increased again once the TFR subsides.
Chanan-Khan et al. [19] observed that prophylaxis with
prednisone decreased the severity but not the incidence of
TFR. Low-dose oral prednisone (20mg daily for 5 days
followed by 10mg for 5 days) was used as TFR prophylaxis
from treatment on days 1 to 10 of cycle 1, TFR prophylaxis
was not given in subsequent cycles. Although exact clinical
impact of TFR remains uncertain, the authors noted that the
intensity of the TFR appeared to be correlated with a higher
probability of achieving a CR; despite a higher CR rate their
analysis did not demonstrate any benefit in the PFS in the
TFR group. Table 1 summarizes the results from clinical trials
using lenalidomide alone in CLL patients.
3.2. Lenalidomide in Combination in CLL. Lenalidomide has
been shown to activate NK cells and one of its postulated
mechanisms of action is increased antibody-dependent cellu-
lar cytotoxicity (ADCC). Thus, lenalidomide would seem an
appealing therapeutic agent to add to rituximab treatment,
which is known to induce ADCC of CD-20-expressing CLL
cells [20]. However a recent laboratory study suggested
a potential antagonism between these two agents if used
simultaneously with CLL cells, since lenalidomide down-
regulated CD20, with a reduction in NK mediated ADCC of
rituximab-treated CLL cells [21].
Clinical trials report that combined treatment with lena-
lidomide and rituximab improves activity and decreases the
toxicity of lenalidomide. Ferrajoli et al. [22] investigated
the combination lenalidomide plus rituximab in 60 patients
with relapsed or refractory CLL. They treated patients with
rituximab weekly for 1 cycle and then once every 4 weeks
during subsequent cycles. Lenalidomide was administered
at dose of 10mg daily starting on day 9 of cycle 1 and
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Table 1: Selected clinical trials using lenalidomide alone for treatment of CLL. NR: not reported.
Study Regimen
No. of
patients
TLS all
grades
TFR all
grades
Hematologic side
eﬀects grade 3/4
OR
(%)
CR
(%)
OS (%) PFS (%)
Chanan-Khanet al. [14]
Phase II
relapsed/refractory CLL
5mg/d escalated
to 25mg/d
45 5% 58%
Neutropenia 70%
thrombocytopenia
45% anemia 18%
47 9 NR NR
Ferrajoli et al. [6]
Phase II
relapsed/refractory CLL
10mg/d escalated
to 25mg/d
44 0 12%
Neutropenia 41%
thrombocytopenia
15% anemia 3%
32 7
73 (with a median
follow-up time of 14
months)
NR
Chen et al. [16]
Phase II untreated CLL
2.5mg/descalated
to 10mg/d
25 0 88%
Neutropenia 72%
thrombocytopenia
28% anemia 20%
56 0
92 (estimated 2
years OS)
89 (estimated
2 years PFS)
Aue et al. [17] Phase II
relapsed/refractory CLL
20mg/d lowered
to 10mg/d
33 0 53%
Neutropenia 56%
thrombocytopenia
30% anemia 15%
NR NR NR NR
Badoux et al. [18]
phase II (elderly)
untreated CLL
5mg/d escalated
to 25mg/d
60 0 52%
Neutropenia 34%
thrombocytopenia
12% anemia <1%
65 10
88 (estimated 2
years OS)
60 (estimated
2 years PFS)
continuing daily for 12 cycles. The ORR was 64%, with
8% CR. Data suggest that this combination is superior to
the single-agent lenalidomide. The most frequently observed
toxicity was neutropenia, occurring in 68% of patients.
Twenty-two patients experienced low-grade tumor flare.
Frontline lenalidomide plus rituximab in patients with
CLL was reported by James et al. [23] in 37 patients.
Lenalidomide was started at a dose of 2,5mg daily with an
escalation up to 5mg and 10mg on day 8, if tolerated, every
21 days of a 28-day cycle for a total of 7 cycles. Patients
received lenalidomide for 21 days in 35-day cycle for the first
cycle, then for 21 days in 28-day cycles for other 6 cycles.
During the first cycle rituximab was given 50mg/m2 on day
29, and 325mg/m2 on day 31, 375 mg/m2on day 33. During
the second cycle rituximab was administered 375mg/m2
weekly and on day 1 during remaining cycles. Early results of
the ongoing study suggest that lenalidomide-plus-rituximab
immunotherapy is tolerable. The most common grade 3/4
adverse events (AE) were neutropenia (18 pts), anemia
(5 pts), and thrombocytopenia (4 pts). There were no cases
of neutropenic fever, sepsis, or bleeding. Nonhematologic
grade 3/4 AEs included infection (3 pts), rash (2 pts), and
pulmonary embolus (2 pts). The protocol was amended to
include aspirin prophylaxis. Most frequent AEs (all grades)
were the TFR (21 pts), fatigue (19 pts).
As a consequence of biological and clinical synergism
of lenalidomide and anti-CD 20 monoclonal antibody, a
combination with the humanized anti-CD20 monoclonal
antibody ofatumumab was evaluated in a phase II trial [24].
Ofatumumab was given weekly, starting at 300mg in the first
week, then at 1000mg weekly, then monthly for 6 months
and lastly every 2 months up to 24 months. Lenalidomide
was given at a dose of 10 mg daily continuously from day 9 of
cycle 1 with treatment duration of 24 months. The ORR was
63% with 2 patients achieving a CR. Toxicity was tolerable,
with 50% of patients developing grade 3 or 4 neutropenia.
TFR was limited to grade 1 in 2 patients.
In the GIMEMA LLC606 phase I clinical trial patients
were treated with lenalidomide, cyclophosphamide, and flu-
darabine [25]. The maximal tolerated dose of lenalidomide
was 5mg. The response rate observed in nine patients was
67%, with 33% CR.
Brown et al. [26] initiated a small phase I study that inves-
tigated the combination of lenalidomide with fludarabine
and rituximab for untreated patients with CLL. A low dose of
lenalidomide (2,5mg) was given daily for 21 days in 28 days
cycles, with fludarabine 25mg/m2 on days 3–5 and rituximab
375mg/m2 on day 1. The trial had to be closed due to signif-
icant myelotoxicity and idiosyncratic tumor flare reactions.
Another trial by Egle et al. [27] combined 6 cycles of
fludarabine, lenalidomide, and rituximab. Lenalidomide was
administered at a starting dose of 2,5mg daily (days 7–21
in cycle 1) and escalated up to 25mg/day from days 1–21 of
the following cycles. After induction treatment, maintenance
with lenalidomide and rituximab for 6 months was planned.
Preliminary data show that all ten treated patients achieved
at least a PR, except for one patient with Richter transfor-
mation; but 50% of patients received a reduced lenalidomide
dose due to toxicity.
A phase I study from the German CLL study group [28]
used the bendamustine-rituximab (BR) backbone and added
lenalidomide to it. This might be an option for patients
with relapse or even refractory CLL. Lenalidomide was given
orally for 7 days followed by rituximab 375mg/m2 on day
1 in addition to bendamustine 90mg/m2 intravenously on
days 1 and 2 and lenalidomide orally daily every 28 days
for a total of 6 cycles. After 6 cycles of bendamustine, lena-
lidomide, and rituximab, lenalidomide monotherapy was
administered as continued therapy for an additional 6 cycles
as tolerated or until disease progression.
Blum et al. [29] conducted a phase I study in which
flavopiridol was given in combination with lenalidomide
in 21 patients with relapsed or refractory B-cell CLL/SLL.
Flavopiridol was administered at 60 mg/m2 on days 1, 8,
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Table 2: Selected clinical trials using lenalidomide in combination for treatment CLL. NR: not reported.
Study Regimen
No. of
patients
TLS all
grades
TFR all
grades
Hematologic side eﬀects
grade 3/4
OR
(%)
CR
(%)
OS
(%)
PFS
Ferrajoli et al. [22] phase II
relapsed/refractory CLL
10mg/d Lenalidomide +
rituximab weekly
59 1,7% 37%
Neutropenia 68%
thrombocytopenia 22%
anemia 10%
64 8 NR NR
Badoux et al. [24] phase II
relapsed/refractory CLL
10mg/d lenalidomide +
ofatumumab weekly
16 NR 13%
Neutropenia 50%
anemia 13%
63 13 NR NR
Blum et al. [29] phase I
relapsed/refractory CLL
2.5mg/d escalated to
25mg/d lenalidomide +
flavopiridol
15 14% 7%
Neutropenia 86%
thrombocytopenia 38%
anemia 38%
46 0 NR NR
GIMEMA LLC 606 [25]
phase I
relapsed/refractory CLL
2.5mg/d escalated to
15mg/d lenalidomide +
cyclophosphamide +
fludarabine
9 0 11%
Transient grade 3-4
neutropenia in the majority
of pts
67 33 NR NR
Egle et al. [27] phase
untreated CLL
2.5 mg/d escalated to 25
mg/d lenalidomide +
fludarabine + rituximab
10 0 0 Neutropenia 70% 90 0 NR NR
and 15 during first cycle and from second cycle at 60mg/m2
on days 3, 10, and 17 plus, starting at cycle 2, lenalidomide
with an initial dose of 2,5mg escalated to 25mg for 21
days of these 28-day cycles. Thirteen patients had del(17p)
and 8 patients had del (11q). Seventeen patients completed
two or more cycles of therapy (median 3, range 2–8),
receiving 2,5mg (6 pts), 5,0mg (7 pts), and 7,5mg (4 pts)
of lenalidomide. Grade 3-4 toxicities consisted of neutro-
penia (86%), diarrhea (62%), reversible transaminitis in
≤7 days (57%), anemia (38%), thrombocytopenia (38%),
hyperglycemia (38%), infection without neutropenia (24
%), febrile neutropenia (14%), TLS not requiring dialysis
(14%), and fatigue (14%). Grade 1 tumor flare occurred
in 1 pt and did not require additional steroids or cessation
of lenalidomide. The ORR was 46% with no CRs. Partial
responses were observed in 7 patients, including 4 patients
with del (17p). In conclusion, combined flavopiridol and
lenalidomide was well tolerated, with activity in patients with
previously treated, cytogenetically high-risk CLL.
A prospective, nonrandomized, phase II study by Shana-
felt et al. [30] presented data about lenalidomide consol-
idation following a PCR (pentostatin, cyclophosphamide,
rituximab) induction. Data from this trial were compared
with results of an historic trial of PCR without lenalidomide
showing an improvement in quality of response and time to
retreatment.
Patients with previously untreated CLL (n = 44) received
induction therapy with the frontline regimen most com-
monly used at the Mayo Clinic, pentostatin 2mg/m2, cyclo-
phosphamide 600mg/m2, and rituximab 375mg/m2 every
3 weeks for 6 cycles. Responding patients were eligible for
consolidation therapy with lenalidomide at a starting dose
of 5mg/day with escalation to 10mg/day as tolerated for
6 months. Thirty-four patients (77%) started lenalidomide
and completed a median of 7 cycles of consolidation therapy.
Among patients who started lenalidomide consolidation
following PCR, the freedom from retreatment at 12 months
was 95% (95% confidence interval: 88% to 100%). The study
investigators compared these findings to historic data from a
trial of PCR induction therapy without lenalidomide consol-
idation [31]. In that study of 64 patients with CLL, the free-
dom from retreatment at 12 months was 86%. Cytopenias
were the most frequent grade ≥3 adverse events considered
possibly associated with lenalidomide consolidation: grade 3
neutropenia and thrombocytopenia occurred in 41% and 9%
of patients, respectively; while grade 4 neutropenia interested
21% of patients. Therefore, the study authors concluded that
lenalidomide consolidation appeared to improve the quality
of response to induction therapy with PCR.
Another ongoing study which evaluates lenalidomide as
maintenance therapy in CLL patients was the CONTINUUM
study [32]: a phase 3, multicenter, randomized, double-
blind, placebo-controlled, parallel-group study of the eﬃ-
cacy and safety of lenalidomide as maintenance therapy for
patients with B-cell chronic lymphocytic leukemia following
second-line therapy. In the experimental arm lenalidomide is
given on days 1–28 of a 28 day cycle until disease progression
or unacceptable toxicity. Table 2 summarizes the results from
clinical trials using lenalidomide in combination regimens in
CLL patients.
4. Conclusions
Lenalidomide proved to be eﬀective in CLL as single agents
or in combination with various chemo immunotherapeutic
regimens. There were several concerns regarding toxicity,
but modified protocols with low starting dose and gradual
dose escalation suggest good tolerability. Myelosuppression
was the predominant toxicity associated with lenalidomide.
Tumor flare was also a problem with lenalidomide therapy,
but it can be controlled by gradual dose-escalation and
prophylactic corticosteroids in the patients who experienced
tumor flare in previous cycles. However, further studies are
needed to establish the most eﬀective dose and schedule of
this agent.
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Lenalidomide might have a place in the first-line setting
in older patients or as second-third line agent for patients
treated with frontline chemoimmunotherapy. Currently,
chemoimmunotherapy represents the standard first-line
therapy for young and fit CLL patients, but patients who
became refractory to fludarabine or carry deletion/mutation
of TP53 and older or unfit patients could profit from alter-
native treatments, including, lenalidomide-based regimens.
Therapeutic strategies including consolidation treatment
are becoming more important in the treatment of CLL,
particularly in the frontline setting. There is a greater number
of complete remissions (CRs) with the new chemoim-
munotherapy combinations, and therefore prolonging the
duration of PFS becomes a more interesting goal. In this con-
text, ongoing promising studies [29, 30] are evaluating the
role of lenalidomide as consolidation/maintenance therapy.
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